Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of its late-stage trial.
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years of dominance by a handful of "Magnificent 7" companies, the tide has turned toward the "median stock,
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Dianthus Therapeutics Q2 2025 earnings show revenue miss but EPS in line. Cash reserves strong, key clinical trials progressing with major data readouts expected in 2025-2026.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
